The primary aim of this proposal is to determine the potential of the Conus peptide Kappa-PVIIA as therapeutic. As a first step in determining the therapeutic potential of Kappa-PVIIA we intend to examine the ability of the peptide to protect excised rabbit hearts against periods of oxygen depletion. Based on the results of this study the experiments will be repeated in an anesthetized rabbit model. In addition the stability of the peptide in solution will be assessed at different temperatures. In phase II we propose to carry out further in vivo characterization of kappa-PVIIA in animal models that more closely mimic human disease conditions.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HL065793-01
Application #
6210884
Study Section
Special Emphasis Panel (ZRG1-SSS-Z (01))
Project Start
2000-09-25
Project End
2002-03-24
Budget Start
2000-09-25
Budget End
2002-03-24
Support Year
1
Fiscal Year
2000
Total Cost
$99,748
Indirect Cost
Name
Cognetix, Inc.
Department
Type
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84108